Company intelligence / Profile preview

Momotaro-Gene Inc.

Okayama, Okayama, Japanmt-gene.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

The company has completed enrollment in its Phase II trial for mesothelioma in the USA. Their Ad-SGE-REIC clinical Phase I/IIa trial for malignant neuroglial tumors at Okayama University Hospital has been completed. The US FDA granted Orphan Drug Designation for MTG-201 for the treatment of malignant mesothelioma in 2015.

Therapeutic areas: Oncology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

4 assets

MTG201

3 more assets in the full pipeline.

Request access →

Partnerships

KYORIN Pharmaceutical Co. Ltd.

Beyond the preview

Go deeper on Momotaro-Gene Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Momotaro-Gene Inc..

Explore the full profile